Trial Profile
Phase 3 Study Investigating the Efficacy and Safety of TAVT-45 (Abiraterone Acetate) Granules for Oral Suspension (Novel Abiraterone Acetate Formulation) Relative to a Reference Abiraterone Acetate Formulation in Patients With mCSPC & mCRPC
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Abiraterone acetate; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms TAVT45CO2
- Sponsors Tavanta Therapeutics
- 06 Jun 2023 Preliminary results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2023 According to a Tavanta Therapeutics media release, detailed results from this trial will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2023.
- 05 Jan 2023 According to a Tavanta Therapeutics media release. company intends to present detailed results from this study at an upcoming medical meeting, as well as submit for publication.